Engineering light-controllable CAR T cells for cancer immunotherapy

Area of Science:

• Immunology
• Molecular Biology
• Biotechnology
• Cancer Research

Background:

• Chimeric antigen receptors (CARs) on T cells offer targeted cancer immunotherapy.
• Limitations exist for CARs targeting solid tumors, potentially causing severe adverse effects.
• Precise control over CAR T cell activation is crucial for safety and efficacy.

Purpose of the Study:

• To develop a novel gene regulation system for controlling CAR T cell activation.
• To create a light-inducible system for noninvasive modulation of CAR T cell function.
• To enhance precision and safety in CAR T cell-based cancer immunotherapy.

Main Methods:

• Development of a light-inducible nuclear translocation and dimerization (LINTAD) system.
• Demonstration of light-controllable gene expression in human embryonic kidney 293T and Jurkat T cell lines.
• Optimization of the LINTAD system for primary human T cells and in vitro/in vivo testing.

Main Results:

• The LINTAD system successfully enabled light-controllable gene expression and functional modulation.
• Pulsed light stimulation activated LINTAD CAR T cells, demonstrating potent cytotoxicity against cancer cells.
• The system proved effective in both in vitro and in vivo experimental models.

Conclusions:

• The LINTAD system provides an efficient, noninvasive method for controlling gene activation.
• This inducible system enables precise activation of CAR T cells for enhanced cancer immunotherapy.
• The LINTAD system holds promise for developing safer and more effective precision cancer treatments.